Rocket PharmaceuticalsRCKT
RCKT
About: Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
Employees: 299
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
172% more call options, than puts
Call options by funds: $3.92M | Put options by funds: $1.44M
168% more repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 41
37% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 35
4% more funds holding
Funds holding: 224 [Q4 2024] → 234 (+10) [Q1 2025]
2.06% less ownership
Funds ownership: 103.1% [Q4 2024] → 101.03% (-2.06%) [Q1 2025]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 2 (-1) [Q1 2025]
48% less capital invested
Capital invested by funds: $1.38B [Q4 2024] → $722M (-$655M) [Q1 2025]
Research analyst outlook
12 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$2.50
15%
downside
Avg. target
$19.63
570%
upside
High target
$44
1,402%
upside
12 analyst ratings
8 positive
67%
4 neutral
33%
0 negative
0%
Canaccord Genuity Whitney Ijem | 275%upside $11 | Buy Maintained | 3 Jun 2025 |
B of A Securities Jason Zemansky | 207%upside $9 | Buy Maintained | 28 May 2025 |
BMO Capital Kostas Biliouris | 173%upside $8 | Outperform Maintained | 28 May 2025 |
Scotiabank Greg Harrison | 548%upside $19 | Sector Outperform Maintained | 28 May 2025 |
Leerink Partners Mani Foroohar | 173%upside $8 | Market Perform Downgraded | 28 May 2025 |
Financial journalist opinion
Based on 86 articles about RCKT published over the past 30 days
Neutral
Accesswire
4 hours ago
Did You Lose Money on Rocket Pharmaceuticals, Inc. (RCKT)? Levi & Korsinsky Urges Investors to Act Before August 11, 2025
NEW YORK, NY / ACCESS Newswire / June 15, 2025 / If you suffered a loss on your Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/rocket-pharmaceuticals-inc-lawsuit-submission-form?prid=153132&wire=1&utm_campaign=28 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
5 hours ago
RCKT STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESS Newswire / June 15, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. ("Rocket" or "the Company") (NASDAQ:RCKT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Rocket securities between February 27, 2025 and May 26, 2025, both dates inclusive (the "Class Period").
Neutral
Accesswire
17 hours ago
Investors in Rocket Pharmaceuticals, Inc. (RCKT): Protect Your Rights - Contact Levi & Korsinsky Before August 11, 2025
NEW YORK, NY / ACCESS Newswire / June 14, 2025 / If you suffered a loss on your Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/rocket-pharmaceuticals-inc-lawsuit-submission-form?prid=153101&wire=1&utm_campaign=11 or contact Joseph E. Levi, Esq.
Neutral
Business Wire
1 day ago
RCKT INVESTOR ALERT: Robbins Geller Rudman & Dowd Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements re: Rocket Pharm business & prospects, resulting in its stock trading at inflated prices.
Neutral
GlobeNewsWire
1 day ago
ROCKET ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Rocket Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ:RCKT) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Rocket securities between February 27, 2025 to May 26, 2025, both dates inclusive (the “Class Period”). Investors have until August 11, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Neutral
GlobeNewsWire
1 day ago
RCKT Investor Notice: Robbins LLP Reminds Shareholders of the Class Action Lawsuit Against Rocket Pharmaceuticals, Inc.
SAN DIEGO, June 13, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 7, 2025 and May 26, 2025. Rocket is a fully integrated, late-stage biotechnology company focused on the development of gene therapies, with direct on-target mechanism of action and clear clinical endpoints, for rare and devastating diseases.
Neutral
Accesswire
1 day ago
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Urged to Join Class Action Before August 11, 2025 - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / June 13, 2025 / If you suffered a loss on your Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/rocket-pharmaceuticals-inc-lawsuit-submission-form?prid=153081&wire=1&utm_campaign=22 or contact Joseph E. Levi, Esq.
Neutral
GlobeNewsWire
1 day ago
ROSEN, A LEADING LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 11, 2025.
Neutral
Accesswire
1 day ago
Join Class Action to Recover Losses From Rocket Pharmaceuticals, Inc. (RCKT) - Contact Levi & Korsinsky Before August 11, 2025
NEW YORK, NY / ACCESS Newswire / June 13, 2025 / If you suffered a loss on your Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/rocket-pharmaceuticals-inc-lawsuit-submission-form?prid=153070&wire=1&utm_campaign=31 or contact Joseph E. Levi, Esq.
Neutral
GlobeNewsWire
1 day ago
RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or “the Company”) (NASDAQ: RCKT) and certain of its officers.
Charts implemented using Lightweight Charts™